Managing Complications of Chemotherapy Discussed on CME Webcast

OSUWexnerbloglogo2014 Managing Complications of Chemotherapy Discussed on CME Webcast. On this CME webcast, to update us is medical oncologist and Associate Professor of Internal Medicine from the Ohio State University and the James Cancer Hospital, Dr. Erin Bertino. And also from the James Cancer Hospital, Assistant Professor of Internal Medicine, Dr. Edmund Folefac.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: RECOGNIZE the differences in toxicity for three categories of oncology therapy: cytotoxic chemotherapy, targeted therapy, and immunotherapy; and UNDERSTAND basic management of the most common toxicities of chemotherapy, targeted therapy, and immunotherapy.

You’ll also learn about the following:

  • Evolution of targeted therapies and immunotherapy
  • What to expect with cancer treatment

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

On-line Enduring Material Discusses Update On Cancer Survivorship Principles In Primary Care

OSUWexnerbloglogo2014 On-line Enduring Material Discusses Update On Cancer Survivorship Principles In Primary Care. On this CME webcast, we’re going to learn about the special needs of cancer survivors. We’re delighted to welcome medical oncologist and Associate Professor of Internal Medicine from the Ohio State University and James Cancer Hospital, Dr. Maryam Lustberg. And also general internist, pediatrician, and Assistant Professor of Internal Medicine from OSU, Dr. Heather Saha.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: DISCUSS the needs of cancer survivors throughout the cancer continuum; DISCUSS way to improve PCP and oncologist collaboration and communication.

You’ll also learn about the following:

  • The role of the primary care physician in cancer survivorship
  • Managing fatigue in the cancer survivor
  • Special considerations for survivors of pediatric cancers
  • Healthy diets for cancer survivors
  • Chemotherapy and peripheral neuropathy
  • Radiation effects on long-term health
  • Economic and financial implications of being a cancer survivor
  • Cancer survivors and sexual health
  • Cancers that can have late relapse

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

CME Webcasts Teaches on Cardiomyopathy

OSUWexnerbloglogo2014CME Webcasts Teaches on Cardiomyopathy. On this CME webcast, we are going to give you the information you need to be able to recognize cardiomyopathy in your patients and then to be able to identify the specific cause of their cardiomyopathy. Joining our moderator in the studio are two cardiologists from the Ohio State University. Dr. Sitaramesh Emani is an Assistant Professor of Internal Medicine and the Director of Heart Failure Clinical Trials at Ohio State. And Dr. Brent Lampert is an Assistant Professor of Internal Medicine and the Associate Program Director for the heart failure and transplant fellowship.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: UNDERSTAND the common presenting signs and symptoms of cardiomyopathy; and REVIEW the diagnostic work up for cardiomyopathy.

You’ll also learn about the following:

  • Common causes of cardiomyopathy
  • Initial diagnostic steps in cardiomyopathy
  • Follow up imaging in patients with cardiomyopathy
  • Myocardial sarcoidosis
  • Physical examination of hypertrophic cardiomyopathy
  • Takotsubo cardiomyopathy
  • Diagnosing restrictive cardiomyopathies
  • Significance and work up of diastolic dysfunction
  • Chemotherapy-induced cardiomyopathy
  • Chagas Disease (Trypanosoma infection)

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Learn about Oncologic Emergencies on Webcast

OSUWexnerbloglogo2014 Learn about Oncologic Emergencies on Webcast. In the 70 years since Goodman and Gilman gave that first dose of nitrogen mustard chemotherapy, we have come a long, long way in oncologic treatment. Today, we can cure cancers that even 10 years ago were considered fatal. But cancers still make our patients incredibly ill and they still cause our patients to die. On this CME webcast, we’re going to discuss some of the emergencies that cancer creates in our patients, how to recognize them, and how to treat them. Joining Dr. Jim Allen, in the studio, we’re delighted to welcome today’s guests. First, we have Dr. Luca Delatore who is an Assistant Professor of Emergency Medicine from the Ohio State University and is the Medical Director of the James Cancer Hospital Emergency Department. Second, we have Dr. Joseph Flynn. For the past 15 years, Dr. Flynn has been an Associate Professor of Internal Medicine in the OSU Division of Hematology and he has just been appointed as the Physician in Chief and Executive Director of Norton Cancer Institute at the Norton Health System in Kentucky.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: RECOGNIZE the different types of oncologic emergencies; and UNDERSTAND the initial treatments for oncologic emergencies and need for emergent consultation.

You’ll also learn about the following:

  • Common cancer emergencies
  • Initial imaging studies for superior vena cava syndrome
  • Initial imaging studies for suspected brain metastases
  • Antibiotic selection in neutropenic fever and sepsis
  • Hyperleukocytosis and leukostasis
  • Approach to the bleeding chemotherapy patient
  • Disseminated intravascular coagulation
  • Common radiation therapy complications
  • Approach to the cancer patient with altered mental status

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

New Developments in Lung Cancer Treatment

OSUWexnerbloglogo2014 New Developments in Lung Cancer Treatment. Lung cancer now accounts for 14% of all cancers but it is the most common cause of cancer death, In fact, more people die each year from lung cancer than from colon cancer, breast cancer, and prostate cancer combined. The 5-year survival rate of lung cancer is only 18% but the good news is that we have a lot of new medications that are giving patients with lung cancer longer and better lives. On our CME webcast, to discuss new treatments in lung cancer, are two of Ohio State’s experts in the management of lung cancer. Joining our moderator, Dr. Jim Allen, we have Dr. Greg Otterson who is a Professor of Internal Medicine from the Division of Medical Oncology and Dr. Erin Bertino, an Assistant Professor of Internal Medicine, also from the Division of Medical Oncology.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: GAIN an understanding of the importance of genomic testing in the initial workup of patients with lung cancer. EXPLAIN the evolving role of immune mediated therapy in lung cancer; RECOGNIZE the clinical benefit for patients receiving targeted therapies; and DESCRIBE the patient characteristics commonly associated with actionable mutations in lung cancer.

You’ll also learn about the following:

  • The most fatal of all common cancers
  • Evolving chemotherapy treatment of lung cancer
  • Sub-classifying adenocarcinomas
  • Squamous cell lung cancer treatment
  • Large cell undifferentiated lung cancer

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.